tag:blogger.com,1999:blog-2194731303325969885.post6103534835222044927..comments2023-11-03T03:44:37.350-07:00Comments on Popgen ramblings: Common variants, when do we stop looking?Graham Coophttp://www.blogger.com/profile/05140268044719927398noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-2194731303325969885.post-74158639764957850712008-04-07T07:52:00.000-07:002008-04-07T07:52:00.000-07:00Thanks. Although, using common variation to priori...Thanks. <BR/><BR/>Although, using common variation to prioritise rare variants is perhaps less helpful if the aim is to characterise the pathway. Though perhaps large effect mutations are easier to functionally analyse. <BR/><BR/>I agree that GWAS are accumulating great resources for resequencing. However, I imagine that legally getting a patient's consent for a GWAS is easier than for a Graham Coophttps://www.blogger.com/profile/05140268044719927398noreply@blogger.comtag:blogger.com,1999:blog-2194731303325969885.post-31343893275940143322008-04-07T05:36:00.000-07:002008-04-07T05:36:00.000-07:00Great post, G - I particularly like the point abou...Great post, G - I particularly like the point about using genes identified in GWAS to prioritise variants in sequencing-based studies. Figuring out which variants are functional is going to be a real challenge in the sequencing era, so any extra sources of information will be useful.<BR/><BR/>I'd add one further motivation for continuing the GWAS effort, even in the face of diminishing returns: Danielhttps://www.blogger.com/profile/07276690118219000204noreply@blogger.com